Daqing Cai

CAI Daqing joined Legend Capital in May 2011 as a Director and now he is an Executive Director. Cai Daqing focuses on investment opportunities in the healthcare sector and he led LC's investments in Berry Genomics and Ustar Biotechnologies (Hangzhou). Prior to joining Legend Capital, Cai Daqing worked with SBI-SDJB, a joint venture of SBI Group and Beida Jadebird Group as a Managing Director. He also worked with SinoChem (Hong Kong) and Booz & Co. in senior management positions. He was a board member and CFO of Beijing Genomics Institute as well. Cai Daqing holds a Ph.D. degree from University of California, Berkeley, an MBA from Yale University and a B.S. degree from University of Science and Technology of China.